Dermata Therapeutics Q1 2026 Earnings NarrowerthanExpected Loss Supports Ongoing Clinical Development PRFX Q2 2024 Earnings EPS Misses Estimates as Company Continues Development Stage NTNX Q1 2026 Earnings Strong EPS Beat Driven by Operational Efficiency ATLCP Q1 2026 Earnings Earnings Per Share Surpasses Estimates by Nearly 26 Biogen Q1 2026 Earnings Strong EPS Beat Drives PostMarket Rally UMBFO Q1 2026 Earnings Preferred Shares Report Strong EPS Beat